Precision BioSciences stock gains as market cap tops 200 million USD

Precision BioSciences stock (ISIN US74019P1084) is currently valued by the market at around 0.20 billion USD, with recent data pointing to a share price in the mid 7 dollar range as of early September 2026 and a market capitalization of about 205.6 million USD.

Market value and recent price levels

According to market capitalization data compiled by CompaniesMarketCap, Precision BioSciences has a market cap of 0.20 billion USD as of September 2026, placing it among smaller listed biotech names by global ranking. The same overview notes that the company’s market cap for 2026 is up by 101.95%, highlighting how the equity value has expanded compared with the previous year.

Complementing this, a recent price snapshot from Indmoney’s DTIL share price page shows a previous close of 7.45 USD, an opening price of 7.50 USD and a latest quoted share price of 7.37 USD at the close of the market on September 4, 2026. On that trading day, the stock touched an intraday high of 7.54 USD and a low of 7.23 USD, underlining that the current price level sits slightly below the previous close but still within a narrow trading band.

Trading range and investor perspective

The same Indmoney overview indicates that Precision BioSciences had a market capitalization of about 205.6 million USD as of its latest update in early September 2026, which aligns with the 0.20 billion USD figure seen in the broader market cap statistics and gives investors a consistent picture of the company’s equity value at current prices. For retail investors, the key takeaway is that the company now trades with a market value above the 200 million USD threshold while the share price remains in single-digit territory, an unusual combination that reflects both past volatility and recent gains.

Although detailed intraday percentage moves are not the central focus of these data snapshots, the CompaniesMarketCap statistics explicitly state that Precision BioSciences’ 2026 market capitalization is up by 101.95% compared with the prior year’s level. This quantified comparison suggests that, even with day-to-day fluctuations such as the small drop from 7.45 USD to 7.37 USD observed on September 4, 2026, the broader trend over the year has been one of significant appreciation in the company’s market value.

Therapeutic focus and pipeline context

Precision BioSciences operates as a biotechnology company focused on gene-edited cell therapies, and the DTIL stock reflects investor expectations around its clinical pipeline and partnering activities. While the very latest quarterly numbers are not detailed in the price-centric portals, the company’s investor relations site outlines a portfolio aimed at oncology and genetic diseases, where allogeneic cell therapies and in vivo gene editing are central themes.

For investors looking at the stock today, the combination of a roughly 7.37 USD share price as of September 4, 2026 and a market cap around 205.6 million USD indicates a modestly capitalized biotech that remains sensitive to clinical milestones, partnering announcements and funding conditions. This positioning means that news on trial progress or licensing deals could quickly translate into changes in the market value, even when the absolute price move per share appears small in dollar terms.

Representative product and technology angle

One representative focus of Precision BioSciences is its gene-edited cell therapy platform built on proprietary editing technologies. This platform underpins investigational products designed to target malignant cells in hematologic cancers and solid tumors, with the aim of offering off-the-shelf cell therapies that can be manufactured at scale. By emphasizing allogeneic solutions rather than patient-specific autologous approaches, the company seeks to broaden access and potentially lower treatment costs over time.

In practical terms, this orientation toward scalable gene-edited cell therapies is a key reason why investors continue to follow Precision BioSciences stock despite its relatively small market capitalization. The value attributed to DTIL today reflects not only recent trading levels around the mid 7 dollar range but also the perceived potential of its technology platform to generate future revenue streams once products advance through clinical development and, eventually, regulatory approval.

Current stock level and trading venue

As of the close on September 4, 2026, Precision BioSciences stock traded at 7.37 USD on its US listing, a level slightly below the previous close of 7.45 USD but still consistent with a market cap near 205.6 million USD. For retail investors, this means that the stock remains firmly in the small-cap biotech segment, with price moves that can be meaningful in percentage terms even when the absolute dollar change appears limited.